We are live on ! Find out more
NTHI icon

NeOnc Technologies

4.33 USD
-0.21
4.63%
At close Updated Nov 17, 4:00 PM EST
Pre-market
After hours
4.12
-0.21
4.85%
1 day
-4.63%
5 days
-3.35%
1 month
59.19%
3 months
-11.81%
6 months
-18.91%
Year to date
-51.24%
1 year
-45.6%
5 years
-64.24%
10 years
-64.24%
 

About: NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Employees: 5

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
10 hours ago
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
Objective response rate was 12.5% (3 of 24 patients) by RANO 2.0, compared with 8.3% (2 of 24 patients) in the August topline results Median overall survival was 26.1 months from the start of NEO100 treatment at recurrence, as previously reported CALABASAS, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade IV IDH1-mutant glioma.
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
Neutral
GlobeNewsWire
1 day ago
NeOnc CEO Amir Heshmatpour's 2026 Open-Market Share Purchases Exceed $1.5 Million
CALABASAS, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) today announced that Amir F.
NeOnc CEO Amir Heshmatpour's 2026 Open-Market Share Purchases Exceed $1.5 Million
Neutral
GlobeNewsWire
4 days ago
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
NeOnc (NASDAQ: NTHI) to present findings from 2 investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO)
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
Neutral
GlobeNewsWire
5 days ago
NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market, bringing his recent purchases to 150,000 shares as the company approaches important clinical and regulatory milestones. The latest transactions represent approximately $294,500, with purchases reaching $4.49 per share.
NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
Neutral
GlobeNewsWire
5 days ago
NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100. Two Form 4 filings dated November 12 add important detail to the company's recent insider-buying activity.
NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
Neutral
GlobeNewsWire
6 days ago
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for its experimental intranasal brain cancer treatment NEO100, putting the company's regulatory strategy in focus as it prepares for a randomized Phase 3 study. NeOnc intends to seek FDA feedback on whether its existing clinical and nonclinical evidence could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval for recurrent or progressive IDH-mutant grade 4 astrocytoma.
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
Neutral
GlobeNewsWire
6 days ago
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma.
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
Neutral
GlobeNewsWire
8 days ago
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
DALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for approximately $230,510, according to a newly filed SEC Form 4. The transactions took place on November 5 and 6, with Heshmatpour purchasing 30,000 shares at a weighted average price of approximately $3.17 on the first day and another 40,000 shares at approximately $3.39 on the second.
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
Neutral
GlobeNewsWire
12 days ago
NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
CALABASAS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress, including the upcoming presentation of data from its NEO100 and NEO212 programs at the Society for Neuro-Oncology Annual Meeting.
NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Neutral
GlobeNewsWire
15 days ago
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
DENVER, Nov. 02, 2026 (GLOBE NEWSWIRE) --  ( 247MarketNews.com ) — In a market where the latest investment trends often dominate attention, NeOnc Technologies Holdings (NASDAQ: NTHI) is developing a story that could prove far more meaningful. The clinical-stage biopharmaceutical company is advancing potential treatments for some of the most difficult-to-treat brain cancers while building an ambitious clinical development strategy that could reach approximately 500 patients across 30 hospitals in three countries.
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
Price charts implemented using Lightweight Charts™